← Back to Search

Kinase Inhibitor

Ibrutinib plus Ruxolitinib for Chronic B-Cell Leukemia

Phase 1 & 2
Waitlist Available
Led By David E Spaner, MD
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights

Study Summary

This study involves adding the kinase inhibitor Ruxolitinib to Ibrutinib to treat Chronic Lymphocytic Leukemia (CLL).

Eligible Conditions
  • Chronic B-Cell Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
maximum tolerated dose (MTD) of ruxolitinib in combination with Ibrutinib.
Secondary outcome measures
ability of Ruxolitinib to increase the depth of response to Ibrutinib
Other outcome measures
effect of Ruxolitinib on levels of plasma cytokines and chemokines

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Ibrutinib plus RuxolitinibExperimental Treatment2 Interventions
Patients taking ibrutinib for relapsed CLL will add ruxolitinib twice per day at the dose identified in a preliminary phase I trial for 7 cycles (3 weeks on/2 weeks off).
Group II: Ibrutinib aloneActive Control1 Intervention
Patients will continue to take Ibrutinib for the equivalent period of time.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ruxolitinib
FDA approved
Ibrutinib
FDA approved

Find a Location

Who is running the clinical trial?

Sunnybrook Health Sciences CentreLead Sponsor
656 Previous Clinical Trials
1,551,401 Total Patients Enrolled
NovartisIndustry Sponsor
1,611 Previous Clinical Trials
2,720,999 Total Patients Enrolled
David E Spaner, MDPrincipal InvestigatorSunnybrook Odette Cancer Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients
Dr. David Spaner 2017. "Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02912754.
All > Cll > Chronic Lymphocytic Leukemia
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top